TY  - JOUR
AU  - Veljković, Nevena V.
AU  - Vučićević, Jelica
AU  - Tassini, Sabrina
AU  - Glišić, Sanja
AU  - Veljković, Veljko
AU  - Radi, Marco
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/558
AB  - Introduction: Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1. Areas covered: This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data. Expert opinion: The profound understanding of HIVs entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals.
T2  - Expert Opinion on Drug Discovery
T1  - Preclinical discovery and development of maraviroc for the treatment of HIV
VL  - 10
IS  - 6
SP  - 671
EP  - 684
DO  - 10.1517/17460441.2015.1041497
ER  - 

@article{
author = "Veljković, Nevena V. and Vučićević, Jelica and Tassini, Sabrina and Glišić, Sanja and Veljković, Veljko and Radi, Marco",
year = "2015",
abstract = "Introduction: Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1. Areas covered: This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data. Expert opinion: The profound understanding of HIVs entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals.",
journal = "Expert Opinion on Drug Discovery",
title = "Preclinical discovery and development of maraviroc for the treatment of HIV",
volume = "10",
number = "6",
pages = "671-684",
doi = "10.1517/17460441.2015.1041497"
}

Veljković, N. V., Vučićević, J., Tassini, S., Glišić, S., Veljković, V.,& Radi, M.. (2015). Preclinical discovery and development of maraviroc for the treatment of HIV. in Expert Opinion on Drug Discovery, 10(6), 671-684.
https://doi.org/10.1517/17460441.2015.1041497

Veljković NV, Vučićević J, Tassini S, Glišić S, Veljković V, Radi M. Preclinical discovery and development of maraviroc for the treatment of HIV. in Expert Opinion on Drug Discovery. 2015;10(6):671-684.
doi:10.1517/17460441.2015.1041497 .

Veljković, Nevena V., Vučićević, Jelica, Tassini, Sabrina, Glišić, Sanja, Veljković, Veljko, Radi, Marco, "Preclinical discovery and development of maraviroc for the treatment of HIV" in Expert Opinion on Drug Discovery, 10, no. 6 (2015):671-684,
https://doi.org/10.1517/17460441.2015.1041497 . .